Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,243.00
Bid: 1,244.80
Ask: 1,245.80
Change: 18.80 (1.54%)
Spread: 1.00 (0.08%)
Open: 1,212.40
High: 1,247.00
Low: 1,210.80
Yest. Close: 1,224.20
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

GSK Drug Combination Granted Priority Review Status By US Regulators

16 Sep 13 10:19

UPDATE 1-GSK cancer drug combination wins US priority review

LONDON, Sept 16 (Reuters) - A combination treatment from GlaxoSmithkline for melanoma, the deadliest form of skin cancer, has won priority review from U.S. regulators. The move means the Food and Drug Administration will now decide whether to approve the dual use of Tafinlar, also known as

16 Sep 13 10:07

GSK cancer drug combination gets U.S. priority review

LONDON, Sept 16 (Reuters) - A combination treatment from GlaxoSmithkline for melanoma, the deadliest form of skin cancer, has won priority review from U.S. regulators. GSK said on Monday the Food and Drug Administration had prioritised a review of a combination of dabrafenib and trametinib

16 Sep 13 09:34

Genmab shares jump as FDA grants drug accelerated status

COPENHAGEN, Sept 16 (Reuters) - Shares in Danish biotech firm Genmab jumped 8.5 percent at open on Monday after the company said late on Friday the United States Food and Drug Administration (FDA) had granted its leukaemia drug "Breakthrough Therapy Designation". Breakthrough Therapy Desig

16 Sep 13 07:17

Friday broker round-up UPDATE

ASOS: Panmure Gordon raises target price from 4555p to 5950p maintaining a buy recommendation. AstraZeneca: Jefferies reduces target price from 3200p to 2850p and retains a hold recommendation. Barclays: Jefferies initiates with a target price of 367p and a buy recommendation. Barratt Development

13 Sep 13 08:26

UPDATE 1-Chinese authorities probing German drugmaker Bayer

SHANGHAI, Sept 13 (Reuters) - Chinese authorities visited a local office of German drugmaker Bayer AG in late August to investigate a potential case of unfair competition, the company said on Friday. China's regulators have been probing numerous international and Chinese drugs firms, with i

13 Sep 13 07:50

Generic drug companies win fight to make Pronova's Lovaza

WASHINGTON, Sept 12 (Reuters) - Generic drug companies can develop generic versions of Lovaza, a fish-oil derived drug used to treat high cholesterol, a U.S. appeals court ruled on Thursday. In April 2009, Pronova BioPharma Norge AS filed a patent infringement lawsuit in Delaware against Te

12 Sep 13 16:50

UPDATE 1-China drugmaker Sino Biopharmaceutical investigating TV corruption report

By Adam Jourdan SHANGHAI, Sept 12 (Reuters) - Chinese drug company Sino Biopharmaceutical Ltd has set up a team to investigate allegations broadcast on state television that its majority-owned subsidiary had paid for illegal overseas trips for doctors, it said on Thursday. Regional sa

12 Sep 13 05:32

China drugmaker Sino Biopharmaceutical investigating TV corruption report

By Adam Jourdan SHANGHAI, Sept 12 (Reuters) - Chinese drug company Sino Biopharmaceutical Ltd has set up a team to investigate allegations broadcast on state television that its majority-owned subsidiary had paid for illegal overseas trips for doctors, it said on Thursday. Regional sa

12 Sep 13 04:21

REUTERS SUMMIT-Reckitt Benckiser hungry for new health deals

* CEO expects shakeout in fragmented consumer health market * Company has firepower to do sizeable deals * RB likely to see disposals as well as acquisitions (Adds more comments, background) By Martinne Geller and Ben Hirschler LONDON, Sept 11 (Reuters) - Reckitt Benckis

11 Sep 13 12:50

Broker tips: GlaxoSmithKline, Glencore Xstrata, Whitbread

Panmure Gordon has kept its positive stance on pharmaceuticals group GlaxoSmithKline, despite recent concerns over rising competition from generic versions of its Advair drug, recommending investors to 'buy' on weakness. The broker said that there are still a number of regulatory process steps and

11 Sep 13 11:23

South Africa's Aspen profit rises, it plans Russia campaign

JOHANNESBURG, Sept 11 (Reuters) - South Africa's Aspen Pharmacare said on Wednesday its full-year earnings rose by a quarter, helped by strong performance at home and overseas, and it was planning a push into Russia. Aspen, Africa's largest maker of generic drugs, said diluted headline earn

11 Sep 13 11:08

REUTERS SUMMIT-Reckitt Benckiser hungry for new health deals

By Martinne Geller and Ben Hirschler LONDON, Sept 11 (Reuters) - Reckitt Benckiser Group will be a major player in a coming shakeout of the global consumer health industry and has the capability to do sizeable deals, according to its chief executive. Speaking at the Reuters Consumer

11 Sep 13 10:54

China drugmaker Gan & Lee investigating allegations it paid $130 mln in bribes

By Adam Jourdan SHANGHAI, Sept 11 (Reuters) - Chinese insulin maker Gan & Lee Pharmaceuticals said on Wednesday it was investigating allegations published in a newspaper that it spent around 800 million yuan ($130.72 million) to bribe doctors to promote the firm's drugs over five years.

11 Sep 13 10:11

Broker snap: 'Buy' Glaxo despite fears over generics, says Panmure

Panmure Gordon has kept its positive stance on pharmaceuticals group GlaxoSmithKline, despite recent concerns over rising competition from generic drugs, recommending investors to 'buy' on weakness. GSK's share price sunk 2.5% on Tuesday after the US Food and Drug Administration (FDA) published dra

11 Sep 13 09:42

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.